Expert Interview
A Third Look: Discussing the use of PLUVICTO to treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies.
Ticker(s): NVS- Radiation Oncologist with Intermountain Health
- Manages 50 patients with MCRPC
- Has prescribed Pluvicto to approximately 10 patients
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
